Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 2017

View Archived Issues

INmune Bio licenses checkpoint inhibitor from Xencor

Genentech initiates phase I study of RO-7171009 for GA secondary to AMD

Plexxikon initiates phase Ib/IIa study of PLX-2853 in advanced malignancies

LIBD and VA collaborate in PTSD

Athera initiates phase IIa trial of PC-mAB in patients with arterial inflammation

Astellas, Mitsubishi Tanabe and Daiichi Sankyo establish JOINUS drug repositioning program

Izun reports phase II data on IZN-6N4 in oral mucositis

FDA grants priority review to Gilotrif sNDA

Recursion in research collaboration agreement with Takeda

Safety and pharmacokinetics of ETX-2514 determined in phase I trial

DNA Zika virus vaccine GLS-5700 safe and immunogenic in healthy subjects

FDA issues complete response letter for AcelRx's Dsuvia NDA

Janssen submits NDA for apalutamide for non-metastatic castration-resistant prostate cancer

Natural killer cell levels and activitation are altered in scrub typhus patients

GlaxoSmithKline describes novel integrin antagonists

Japan Science and Technology Agency patents beta-amyloid aggregation inhibitors

University of Minnesota presents new indole and indazole derivatives

Novel apelin receptor agonists synthesized at Bristol-Myers Squibb

CSIR develops novel silicon-containing quinolines

Investment deal to support University of Toronto start-up Janpix

Brexpiprazole begins phase III trials to treat manic episodes associated with bipolar I disorder

Symproic launched in U.S.

Phase IIa results for VDA-1102 in actinic keratosis support progression to phase IIb

Elsalys Biotech acquires Leukotac rights from Jazz

Ardelyx's T3MPO-2 phase III trial of tenapanor for IBS-C meets endpoints

Merck & Co. will not make regulatory filings for anacetrapib

Katholieke Universiteit Leuven, Janssen patent dengue virus replication inhibitors

FDA advisory committee recommends approval of Luxturna gene therapy

NCI grant supports VLP Therapeutics' development of VLP vaccine-based cancer immunotherapy

Final study results show 71% success rate for WTX-101 in Wilson's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...